DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

被引：37
|
作者：
Chapple, C. [1 ]
Wyndaele, J. J. [2 ]
Van Kerrebroeck, P. [3 ]
Radziszewski, P. [4 ]
Dvorak, V. [5 ]
Boerrigter, P. [6 ]
机构：
[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Antwerp, Fac Med, B-2020 Antwerp, Belgium
[3] Univ Med Ctr Maastricht, Maastricht, Netherlands
[4] Med Univ Warsaw, Dept Urol, Warsaw, Poland
[5] Private Obstet Gynecol Clin, Brno, Czech Republic
[6] Astellas Pharma, Med & Clin Dev, Global Dev EU, Leiderdorp, Netherlands
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(10)60758-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
    Hiromi Iitsuka
    Tomoaki Tokuno
    Yoko Amada
    Hiroshi Matsushima
    Masataka Katashima
    Taiji Sawamoto
    Shin Takusagawa
    Marcel van Gelderen
    Takanori Tanaka
    Hideo Miyahara
    Clinical Drug Investigation, 2014, 34 : 27 - 35
  • [32] Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
    Iitsuka, Hiromi
    Tokuno, Tomoaki
    Amada, Yoko
    Matsushima, Hiroshi
    Katashima, Masataka
    Sawamoto, Taiji
    Takusagawa, Shin
    van Gelderen, Marcel
    Tanaka, Takanori
    Miyahara, Hideo
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 27 - 35
  • [33] Re: Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Editorial Comment - Re: Randomized Double-Blind, Active-Controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder Editorial Comment
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2013, 189 (06): : 2204 - 2205
  • [34] Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study
    Jee Soo Park
    Yong Seung Lee
    Cho Nyeong Lee
    Sung Hoon Kim
    Sang Woon Kim
    Sang Won Han
    World Journal of Urology, 2019, 37 : 1665 - 1670
  • [35] Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study
    Park, Jee Soo
    Lee, Yong Seung
    Lee, Cho Nyeong
    Kim, Sung Hoon
    Kim, Sang Woon
    Han, Sang Won
    WORLD JOURNAL OF UROLOGY, 2019, 37 (08) : 1665 - 1670
  • [36] A Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study of Once-Daily Mirabegron 50 mg in Patients with Overactive Bladder
    Yamaguchi, O.
    Hidehiro, K.
    Yukio, H.
    Yasuhiko, I
    Masayuki, T.
    Osamu, N.
    Momokazu, G.
    Osamu, Y.
    Naruhito, S.
    Masaki, Y.
    Ikeda, Y.
    Ohkawa, S.
    UROLOGY, 2012, 80 (03) : S10 - S11
  • [37] A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
    Buller, Harry R.
    Lensing, Anthonie W. A.
    Prins, Martin H.
    Agnelli, Giancarlo
    Cohen, Alexander
    Gallus, Alexander S.
    Misselwitz, Frank
    Raskob, Gary
    Schellong, Sebastian
    Segers, Annelise
    BLOOD, 2008, 112 (06) : 2242 - 2247
  • [38] CLINICAL EFFICACY OF A β3-ADRENOCEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT IN FEMALE PATIENTS WITH OVERACTIVE BLADDER: A RANDOMIZED CROSSOVER STUDY (AN INTERIM REPORT)
    Torimoto, Kazumasa
    Hirayama, Akihide
    Matsumoto, Yoshihiro
    Matsushita, Chie
    Yamada, Atsushi
    Nakagawa, Yoshinori
    Momose, Hitoshi
    Tanaka, Masahiro
    Hosokawa, Yukinari
    Goto, Daisuke
    Fujimoto, Kiyohide
    JOURNAL OF UROLOGY, 2014, 191 (04): : E344 - E344
  • [39] Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a 3-adrenoceptor agonist, in patients with overactive bladder in Asia
    Kuo, Hann-Chorng
    Lee, Kyu-Sung
    Na, Yanqun
    Sood, Rajeev
    Nakaji, Shigeru
    Kubota, Yosuke
    Kuroishi, Kentarou
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 (07) : 685 - 692
  • [40] Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
    Chapple, Christopher R.
    Kaplan, Steven A.
    Mitcheson, David
    Klecka, Jiri
    Cummings, Jana
    Drogendijk, Ted
    Dorrepaal, Caroline
    Martin, Nancy
    EUROPEAN UROLOGY, 2013, 63 (02) : 296 - 305
12345